Proteome analysis is increasingly being used in investigations elucidating the molecular basis of disease, identifying diagnostic and prognostic markers, and ultimately improving patient care. We appraised the current status of proteomic investigations using human samples, including the state of the art in proteomic technologies, from sample preparation to data evaluation approaches, as well as key epidemiologic, statistical, and translational issues. We systematically reviewed the most highly cited clinical proteomic studies published between January 2009 and March 2014 that included a minimum of 100 samples, as well as strategies that have been successfully implemented to enhance the translational relevance of proteomic investigations. Limited comparability between studies and lack of specification of biomarker context of use are frequently observed. Nevertheless, there are initial examples of successful biomarker discovery in cross-sectional studies followed by validation in high-risk longitudinal cohorts. Translational potential is currently hindered, as limitations in proteomic investigations are not accounted for. Interdisciplinary communication between proteomics experts, basic researchers, epidemiologists, and clinicians, an orchestrated assimilation of required resources, and a more systematic translational outlook for accumulation of evidence may augment the public health impact of proteomic investigations.
Proteome analysis aims at elucidating the molecular basis of disease, identifying diagnostic and prognostic biomarkers, and discovering novel drug targets (1) (2) (3) (4) . Proteomic investigations face methodological challenges similar to those of other "-omics" investigations, with additional challenges stemming from the highly compartmentalized, dynamic nature of the proteome and its posttranslational modifications. While the genome is comparably stable, can be assessed with high confidence based on base-pairing, and can be amplified, such approaches do not apply to proteomics. Mining the proteome requires elaborate strategies to either cover the wide, dynamic range of protein abundance or zoom in on particular subsets through fractionation or affinity-based methodologies (5) . These challenges, as well as the limited availability of appropriate samples, have affected the translational potential of many proteomic studies. urine proteome is of higher stability and lower complexity and is particularly informative in urogenital diseases (9, 10) .
Protein stability is a major design consideration (11) . Sampling affects proteases' activity (12) and the activity of other enzymes that modify proteins, like phosphatases (13) . Specimen procurement, storage, and processing protocols should minimize such variability-for example, as implemented in a standard urine collection protocol (14) . Proteolysis may be reduced by adding protease inhibitors and/or manipulating and storing blood or tissue samples at very low temperatures; protease activity at ambient conditions does not significantly affect the proteome in urine (14) . Further, preanalytical variables, such as ischemia time, can influence posttranslational modifications even if global protein expression appears unaffected (15) . Thus, biospecimens must be collected, stored, and processed according to standard operating procedures (16) (17) (18) .
Protein identification and quantification
Currently available proteomic technologies were recently reviewed (19) (20) (21) (22) (23) (24) . The choice of methodology depends on the selection of specimen type and study design. Comprehensive assessment of a complete proteome is hindered by differences in protein physiochemical properties (insoluble proteins cannot be analyzed by techniques requiring proteins in solution) and limitations in dynamic ranges. As shown in Web Figure 1 (available at http://aje.oxfordjournals.org/), preanalytical steps (removal of abundant proteins; centrifugation; affinity and other types of chromatography) are applied to enrich a "subproteome." However, these steps also introduce bias and add variability (25) .
Subsequently, proteins are separated to reduce complexity. Two-dimensional electrophoresis has now largely been replaced by liquid chromatography (LC) and capillary electrophoresis (CE), both being quite complementary (26, 27) . Protein identification and quantification follows, regularly performed by mass spectrometry (MS) (Web Figure 2 ). While small proteins or peptides (<5,000 Da (atomic mass units)) can be directly analyzed using MS, larger proteins have to be cleaved into defined fragments (typically using the protease trypsin, which efficiently cleaves proteins after lysine and arginine) prior to analysis by MS. MS involves application of one of 2 principal ionization methods (matrix-assisted laser desorption/ionization or electrospray ionization (reviewed by Kolch et al. (22) ) in combination with contemporary mass analyzers (ion traps, quadrupole, time-of-flight, Orbitrap (Thermo Fisher, Bremen, Germany), or Fourier transform ion cyclotron resonance, listed here in order of increased resolution and cost). Modern instruments allow the detection of several thousand peptides when coupled with LC or CE.
MS enables sequence-based identification of proteins or peptides (Web Figure 2) (21, 22) and assessment of abundance (Web Figure 1 ; reviewed in references [28] [29] [30] [31] . With tandem mass spectrometry (MS/MS) (21, 32) , an ion (peptide) is selected on the basis of its mass. Energy is furnished, for example, by enabling collision with gas molecules (collisioninduced dissociation) or adding electrons (electron transfer dissociation), which results in ion fragmentation, most frequently at the least flexible bond, the peptide backbone. The derived fragments are then analyzed. The resulting complex spectrum (Web Figure 2) is mapped onto theoretical spectra, based on a protein sequence database. Several software solutions are available for MS/MS data interpretation; their individual strengths and shortcomings are described elsewhere (33) . The interpretation of MS/MS spectra is prone to incorrect assignment of sequences to spectra. Moreover, most MS/ MS spectra cannot be confidently interpreted, because of moderate spectral quality and posttranslational modifications which interfere with identification. To account for false sequence assignment, protein identification should be based on the detection of at least 2 tryptic peptides.
Protein quantification using MS is performed either labelfree, based on the intensity of the MS signal ("ion counting"), or labeled, based on the comparative analysis of labeled proteins/peptides (28) . Labeling approaches employ labeled derivatives of peptides that allow for multiplexing quantification, hence reducing technical variability. However, labels are expensive, and proteome coverage may be lower than with label-free approaches. A variation of the label-based strategy and an alternative to enzyme-linked immunosorbent assay is multiple reaction monitoring: A prototypic tryptic peptide, representing a protein, is analyzed using a triple quadrupole MS in the presence of a stable isotope-labeled reference standard (29) (30) (31) . The signal intensity of a specific fragment ion is assessed in reference to the labeled standard, permitting absolute quantitation.
Emerging new approaches, independent of MS, include the use of specific probes (e.g., antibodies or aptamers) (34, 35) . These approaches are limited by their requirement for a hypothesis, while MS-based analyses allow a hypothesis-free approach. Limitations in the sensitivity and specificity of the antibodies or probes may result in incorrect assessments. However, analysis can be performed in parallel for thousands of antigens. Recent developments in high-throughput production of antibodies (36) and approaches performing repeated, serial assessment of the same tissues for multiple antigens (37) merit attention.
Irrespective of the approach, identification of markers or well-defined signatures (consisting of defined markers) in a baseline "discovery" set of samples must be followed by subsequent validation in a second, independent study population (4, 33) . A report on "discovery" only is of limited, if any, value. Discovery and validation may be performed either using the same platform (e.g., CE-MS) or using different platforms (e.g., LC-MS/MS for discovery and multiple reaction monitoring for validation). In the latter approach (employing 2 different platforms), the performance of the second platform should be established first. Otherwise, a negative result cannot be interpreted: It may reflect failure of either the biomarker or the platform. the classification of a few samples with apparently enhanced accuracy, but overfitting is common. Dakna et al. (41) explored the performance of multimarker classifiers using as a paradigm urinary peptides to assess sex. The study demonstrated that statistical testing, including adjustment for multiple testing, is essential; multiple biomarkers can be combined in a classifier that outperforms single biomarkers; and validation in an independent sample is imperative. Failures of small studies to detect biomarkers often result from variability that interferes with determining effect sizes. Increases in both samples and biomarkers contribute to the development of multimarker classifiers with enhanced accuracy. Of the different algorithms available, high-dimensional classifiers (e.g., support vector machines, artificial neural networks, or random forests (41, 42) ) perform similarly, outperforming linear combinations. Sampson et al. (43) have claimed that overall, support vector machines seem to perform best.
SYSTEMATIC REVIEW OF CLINICAL PROTEOMIC INVESTIGATIONS
To review the current status of clinical proteomic investigations, we conducted a literature search in Medline (National Library of Medicine, Bethesda, Maryland) and the Web of Science Expanded Core Collection (Thomson Reuters, New York, New York) for material published during the last 5 years (January 1, 2009-March 7, 2014). The search query included: ["proteom*"] AND ["biological marker" OR "biomarker"]. Given the expanse of published studies, we decided a priori to focus on the largest studies which have exhibited the greatest impact-those having more than 100 independent samples in discovery and test sets and more than 5 citations per year. Of 1,186 initially retrieved items, 32 studies met inclusion criteria (Figure 1 ). The reviewed evidence is presented according to the technological platform employed.
Capillary electrophoresis-mass spectrometry
Nine eligible studies employed CE-MS for discovery and validation of biomarkers in urine (n = 7), bile (n = 1), and cerebrospinal fluid (n = 1) (44-52). Eight were case-control studies, while 1 cross-sectional study evaluated urinary peptides associated with aging (Table 1 ). Some studies report high classification accuracy-for example, with an area under the curve exceeding 0.90 (2, 18, (53) (54) (55) .
For chronic conditions like chronic kidney disease, coronary artery disease, autosomal dominant polycystic kidney disease, and aging (45, 46, 48, 51) , hundreds of disease-associated urinary peptides may be relevant, potentially displaying the systemic multiorgan changes occurring in disease development. In contrast, relationships between acute diseases (acute kidney injury and preeclampsia) and fewer disease-associated urinary peptides have been observed (44, 49) .
Most studies have employed correction for multiple testing, including false discovery rate approaches (44, 46, 48, 49) or the Westfall and Young maxT procedure (50, 51) . Control groups were often related to the clinical query being investigated. For example, controls for invasive bladder cancer Epidemiologic Design and Analysis for Clinical Proteomics 637 High similarity between aging and chronic kidney disease.
Abbreviations: ATPase, adenosine triphosphatase; AUC, area under the curve; CE, capillary electrophoresis; CI, confidence interval; CSF, cerebrospinal fluid; MS, mass spectrometry.
were persons with noninvasive cancers, cholangiocarcinoma controls were persons with primary sclerosing cholangitis without cholangiocarcinoma, and controls for intensive care unit patients with acute kidney injury were either intensive care unit patients or hematopoietic stem-cell transplant recipients without acute kidney injury (49, 50, 52) . A major advantage of the CE-MS approach is that a single platform (56) is employed for initial identification and subsequent verification. Additionally, more than 20,000 independent CE-MS data sets from controls and persons with various diseases are available (57) .
Two-dimensional electrophoresis-mass spectrometry
Eleven studies employed 2-dimensional electrophoresis-MS for biomarker discovery (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) . For validation, 7 were case-control studies (60, 61, 63, 64, (66) (67) (68) , 3 were cohort studies (58, 59, 62) , and 1 used a cross-sectional design for investigating cerebrospinal fluid biomarkers in Alzheimer's disease (Table 2 ). In the latter study (65) , neuronal cell adhesion molecule, chitinase-3-like 1 protein, chromogranin A, carnosinase I, transthyretin, and cystatin C were confirmed as being significantly associated with Alzheimer's disease, with 4 improving the diagnostic accuracy of amyloid β peptide and τ protein in an independent cohort (65).
The case-control studies identified diagnostic biomarkers for various diseases, including chronic obstructive pulmonary disease, multiple sclerosis, and cancer (e.g., breast, prostate, and colorectal cancer), in diverse specimen types, including tissue (60, 61, 64, 68) , plasma/serum (60, 64, 66, 68) , cerebrospinal fluid (63), and saliva (67) . Several studies encompassed control groups relevant for current diagnostic dilemmas: The control group for identifying diagnostic biomarkers of hepatitis C cirrhosis included patients with either alcoholic cirrhosis or hepatitis B cirrhosis (61) , and the control group for colorectal cancer consisted of colorectal adenoma patients (68) . Controls for disseminated prostate cancer included patients with either nondisseminated disease or benign prostatic hyperplasia (64) . The translational potential of findings is augmented with multimarker panels, as exemplified by Verrills et al. (66) , who assessed a panel of plasma biomarkers (including α 2 -macroglobulin, haptoglobin, ceruloplasmin, and hemopexin) for detecting nonsmoking asthma and chronic obstructive pulmonary disease (area under the curve: 0.80-0.96).
All cohort studies employing 2-dimensional gel approaches investigated prognostic biomarkers in tissue specimens for oncological diseases (58, 59, 62) . Justification for biomarker selection was not always evident: Cheng et al. (58) found 141 apparently different protein spots for hepatocellular carcinoma, identified 89, and selected one of them, N-myc downstream regulated gene 1, for further investigation.
Liquid chromatography-mass spectrometry
Five studies employed LC-MS-based approaches to identify biomarkers (Table 3) for multiple sclerosis and different malignancies (69) (70) (71) (72) (73) . Three studies were case-control investigations (70-72), while 2 were cohort studies (69, 73) .
Comabella et al. (70) investigated pooled cerebrospinal fluid samples from patients progressing to multiple sclerosis and controls, using iTRAQ (AB SCIEX, Framingham, Massachusetts) labeling followed by LC-MS/MS. Among several candidates, chitinase-3-like 1 protein was found to be associated with progression to multiple sclerosis in an independent high-risk cohort of patients with clinically isolated syndrome.
Evaluation of biomarker-added value is pivotal for translational potential but is often hindered by limited statistical power or a questionable rationale for selecting a specific biomarker. For example, Shang et al. (71) claimed improvement in the diagnosis of hepatocellular carcinoma based on α-fetoprotein only, but the study population was small and added value was not demonstrated. Wang et al. (72) investigated the relationship between the previously identified retinoblastoma-associated binding protein 46 and non-smallcell lung carcinoma. While its association with distant metastasis was established in a small cohort, it may have been advantageous to test not the sole novel biomarker but rather the best-performing biomarkers (72) .
The 2 cohort studies employing LC-MS both investigated prognostic markers for oncological diseases, that is, hepatocellular carcinoma and colorectal cancer. Selection of biomarkers for further evaluation may be particularly challenging within this context. Xue et al. (73) investigated the secretome of colorectal cancer cell lines using LC-MS/MS and identified 145 biomarker candidates. Two biomarkers (trefoil factor 3 and growth/differentiation factor 15) were selected (for unclear reasons) for verification in human plasma. Bai et al. (69) initially identified 149 tentative biomarkers. Following additional experiments in independent samples and cell lines, 1 protein (calpain, small subunit 1) was selected as a promising candidate and was then also evaluated in an independent cohort (69).
Immunological approaches
Fifty-seven primarily immunomodulatory proteins were assessed for their ability to distinguish between pancreatic cancer and controls. A 25-protein signature facilitated diagnosis with 88% accuracy (74). Farlow et al. (75) used 2-dimensional gel immunoblots to identify autoantigens associated with non-small-cell lung carcinoma (area under the curve: 93.4%). Controls included patients with osteoarthritis, chronic obstructive pulmonary disease/asthma, and nonneoplastic pulmonary disorders.
Testing of previously reported biomarkers
In 3 studies, investigators evaluated the added value of previously identified diagnostic biomarkers (Table 3 ) (76-78). Moore et al. (77) and Zhu et al. (78) examined the added value of 7 and 28 additional biomarkers, respectively, as opposed to cancer antigen 125 alone, in detecting ovarian cancer. Neither investigation detected any significant improvement in diagnosis. Notably, all biomarkers were discovered using surfaceenhanced laser desorption/ionization (SELDI) technology, which was subsequently found to be of poor accuracy and is essentially no longer being used (25) . Dieplinger et al. (76) tested the added value of apolipoprotein A-IV and afamin, in addition to cancer antigen 125, in diagnosing ovarian cancer in a cohort of 757 subjects. While both biomarkers were significantly Levels of e-FABP5, MCCC2, PPA2, SLP2, and ezrin were significantly increased in patients with lymph node metastatic prostate cancer, while SM22 level was decreased. Table continues associated with ovarian cancer, there was no improvement in diagnostic performance.
CONCLUSIONS Statistical issues
Clinical proteomic investigations are often "high p, small n" studies, involving high-dimensional, non-normally distributed data (79) which often cannot be analyzed with conventional statistical approaches (80) . This problem becomes more pronounced because of the lack of data comparability between different studies, originating from the use of different experimental workflows and platforms. Statistical assessments of proteomic data sets, including approaches for avoiding bias, were recently reviewed (81) . Specific adjustments may be required as a result of the analytical platform, such as the employment of a likelihood framework to account for undetected proteins in proteomic experiments (82) . Distributions are typically tested for normality with either the Shapiro-Wilk test or the Kolmogorov-Smirnov test (83) , corrected with log transformation when applicable (84) . Normally distributed and non-normally distributed variables are compared using parametric (e.g., Student's t test or analysis of variance) or nonparametric (e.g., Wilcoxon-Mann-Whitney test) tests, respectively (83, 85) . Depending on the study design, linear, logistic, or Cox regression models are used to assess continuous, binary, and time-to-event outcomes, respectively. These approaches allow adjustment for potential covariates.
Proteomic investigations generally employ multiple hypothesis testing (84) . Multiple testing correction methods (e.g., Bonferroni correction) or adoption of false discovery rate approaches may improve interpretation of results (85) . The false discovery rate is overly optimistic, resulting in biomarker discoveries which fail validation, as exemplified in an investigation of plasma biomarkers for Alzheimer's disease (86) .
Besides false-positive findings, false-negative findings may also be encountered, particularly in small, underpowered studies (4). Appropriate power calculations, with adjustment for the number of proteins tested, denote the minimal sample size required (84) , and tools specifically for proteomic applications are available (87) . Overly optimistic assumptions in power calculations should be avoided. Although even recent publications suggest that a sample of 6 is sufficient to detect significant proteomic biomarkers (88) , the large number of false-positive reports indicates that such studies are probably underpowered and results are not reproducible. Pooling of disparate samples for enhancing statistical power may cause problems because of Simpson's paradox (4).
Epidemiologic issues
The authors of previous reviews have made suggestions on improving the epidemiologic design and translational potential of clinical proteomic investigations (80, 89) . Many current studies still have cross-sectional designs (including pointprevalence studies). However, methodological challenges in establishing biomarker-disease associations are frequently encountered (90) . Consequently, (nested) case-control studies are often employed instead. Abbreviations: ANXA3, annexin A3; AUC, area under the curve; CHI3L1, chitinase-3-like 1 protein; COPD, chronic obstructive pulmonary disease; CRC, colorectal cancer; CSF, cerebrospinal fluid; 2DE, 2-dimensional electrophoresis; e-FABP5, epidermal fatty binding protein 5; HCC, hepatocellular carcinoma; HSP60, heat shock protein 60; MCCC2, methylcrotonoyl-coenzyme A carboxylase 2; MPFAP-4, human microfibril-associated protein 4; MS, mass spectrometry; NA, not applicable; NDRG1, N-myc downstream regulated gene 1; NrCAM, neuronal cell adhesion molecule; PPA2, inorganic pyrophosphatase 2 isoform 1 precursor; S100A8, calgranulin A; S100A9, calgranulin B; SLP2, stomatin-like protein 2; SM22, antitransgelin; TCTP, translationally controlled tumor protein. The addition of 7 biomarkers to CA-125 did not improve sensitivity for diagnosing ovarian cancer.
Table continues
Putative prognostic biomarkers are optimally assessed in longitudinal cohort studies, like the evaluation of biomarker panels for ovarian cancer (78) . The Food and Drug Administration has approved use of the assay (91); nevertheless, its value is deemed questionable (92) (93) (94) . A link of the markers (the highly abundant plasma proteins transthyretin, apolipoprotein A-I, β 2 -microglobulin, and transferrin) to the biology of ovarian cancer is not evident.
An example of a successful proteomic application tested in both cross-sectional and longitudinal epidemiologic studies is the PRIORITY [Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention of Early Diabetic Nephropathy in Type 2 Diabetic Patients with Normoalbuminuria] Trial (18) (also described below), a prospective study that used a proteomic profile to stratify diabetic patients and guide initiation of treatment to prevent progression of diabetic nephropathy. A 273-urinary-peptide classifier was developed in a cross-sectional study (n = 748) (46); its predictive value was subsequently evaluated in smaller longitudinal cohorts (18, (53) (54) (55) and ultimately in the general population (95) . Biomarkers have also been studied in highrisk cohorts, with expected curtailed latency periods and elevated incidence rates. This was demonstrated by Huber et al. (96) , who evaluated the prognostic value of nuclear matrix protein 22 for urinary bladder cancer in a cohort of chemical workers who had an elevated disease risk due to occupational aromatic amine exposure. Similar validation studies of additional proteomic markers during surveillance for bladder cancer are in progress in the context of TransBioBC (www. transbiobc.org). However, longitudinal, population-based proteomic investigations are often impracticable, as they require collecting many longitudinal specimens, particularly from healthy volunteers. Additionally, when investigating chronic conditions with extended disease latency, use of hard endpoints (as opposed to surrogate outcomes) may require long study intervals (>10 years) and high cost (4). Finally, biological specimens are often affected by extraneous patient and environmental factors (concomitant therapies, adjuvant tests and treatments, etc.) which may alter blood protein composition and, consequently, biomarker assay values (97) . Concomitant assessment of such confounding and/or mediating factors, especially in population studies, is difficult and introduces bias, hindering the interpretation of clinical proteomic findings (98) . Even more so, additional practical and ethical challenges are posed by the collection of bodily specimens requiring invasive procedures (e.g., tissue samples) in the general population. In most implemented proteomic investigations, these challenges are often circumvented by evaluating hospital-based and/or high-risk population groups.
Testing of already collected biobank samples could overcome some obstacles (80) . However, often accessible biobanked samples are not available to the scientific community, and their utility is often impeded by insufficient clinical information for assessing confounding effects. Suggestions for improvement were recently made (99, 100) .
Translational issues
The biomarker context of use frequently remains unspecified and unaddressed by the study design employed. The ability of biomarkers to add value to current clinical standards is rarely assessed. Most investigations primarily address diagnostic performance (discrimination), rather than clinical utility. However, eventual uptake of proteomic biomarkers in clinical practice will require demonstration of added value (89) . Improved discrimination (84) does not necessarily translate to clinical utility. Positive and negative predictive values can offer some hints about the potential applicability of proteomic biomarkers in clinical settings. The gold standard for adopting biomarkers is randomized clinical trials, but these remain rare (101). As mentioned above, the PRIORITY Trial is a large, multicenter, randomized prospective study aiming to examine the value of a proteomic biomarker, CKD273, in combination with therapeutic intervention (18) . A total of 3,280 diabetic patients will be investigated for early-stage chronic kidney disease, using CE-MS-based urinary proteomics to assess 273 urinary biomarkers that are combined in the support vector machine-driven CKD273 classifier. This urinary proteomic classifier was developed and evaluated in several studies (46, (53) (54) (55) 95) , and recently its validity was confirmed in a large, multicenter study of almost 2,000 subjects (102) . Patients with positive test findings will be randomized for therapy with either spironolactone or placebo.
The endpoint (albuminuria) will be evaluated after a 3-year follow-up. Finally, the adoption of biomarkers or classifiers at the public health level requires evidence in support of their costeffectiveness (99, 103, 104) . Cost-effectiveness analyses account for health-care costs, patient outcomes, and quality of life (89, 105) . This is exemplified by Schiffer et al. (106) , who demonstrated a benefit in the cost-effectiveness of urinary biomarkers, as compared with prostate-specific antigen and biopsy, for diagnosing prostate cancer. Such cost-effectiveness analyses are rare to date, since few biomarkers have successfully progressed through the research pipeline (2, 89).
OUTLOOK
Hopefully, proteomic investigations will move from discovery studies with small sample sizes to larger studies with proper validation and evaluation of clinical utility, including randomized trials. Validation of evidence requires the implementation of proper epidemiologic approaches tailored for proteomic investigations. Combinations of multiple -omics platforms are currently being pursued in the context of large collaborative studies-for example, sysVASC for cardiovascular disease (http://www.sysvasc.eu/) and iMODE-CKD for chronic kidney disease progression (http://imodeckd.org/). Interdisciplinary communication between basic researchers, epidemiologists, and clinicians, in combination with an orchestrated assimilation of required resources, is needed to enhance the translational potential of clinical proteomic investigations. The disparity between the large number of clinical proteomic studies published and the few studies that have really indicated clinical potential suggests that a change in the field is required. As outlined recently (107, 108) , a shift from discovery towards verification in large studies is needed. The biomarker should have a clear context of use, be verified in an independent cohort, and be tested in samples reflecting the typical clinical situation. These principles are increasingly being taken up by funding agencies; hence, we expect to see better demonstration of the true impact of clinical proteomics in appropriately powered studies in the near future.
